Servier Pharmaceuticals Revenue and Competitors

Boston, USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Servier Pharmaceuticals's estimated annual revenue is currently $205.4M per year.(i)
  • Servier Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Servier Pharmaceuticals has 1022 Employees.(i)
  • Servier Pharmaceuticals grew their employee count by 5% last year.

Servier Pharmaceuticals's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Servier Pharmaceuticals?

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients' lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all.

keywords:N/A

N/A

Total Funding

1022

Number of Employees

$205.4M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Servier Pharmaceuticals News

2022-04-17 - Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in ...

Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families...

2022-04-17 - Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid ...

(Funded by Agios Pharmaceuticals and Servier Pharmaceuticals; AGILE ClinicalTrials.gov number, NCT03173248. opens in new tab.)...

2022-04-17 - Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1 ...

The study was funded by Agios Pharmaceuticals. Servier Pharmaceuticals has completed the acquisition of the Agios oncology business.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$301.1M10246%N/A
#2
$183M10354%$323.2M
#3
$328.9M1035-3%N/A
#4
$363.3M1038-6%N/A
#5
$211.8M10581%$1000M